



30 May 2025

To,

National Stock Exchange of India Limited, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India E-mail: takeover@nse.co.in Stock Code: NSE – HCG	BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India E-mail: corp.relations@bseindia.com Stock Code: BSE – 539787
---	---

Subject: Disclosures under Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**Listing Regulations**”)

Stock Code: BSE – 539787, NSE – HCG

Dear Sir / Madam,

A. Change in Promoter/ Promoter Group

We refer to our letter dated 23 February 2025 wherein the Company had informed the Stock Exchanges regarding execution of the share purchase agreement between Aceso Company Pte. Ltd. (“**Seller**”), Hector Asia Holdings II Pte. Ltd. (“**Purchaser 1**”) and KIA EBT II Scheme 1 (“**Purchaser 2**”) (Purchaser 1 and Purchaser 2 collectively, “**Purchasers**”) and the Company for the sale of up to 54% of the diluted voting share capital of the Company from Seller to the Purchasers (“**SPA**”).

We now wish to inform you that the transfer by the Seller of: (i) 7,16,77,991 equity shares of the Company to Purchaser 1; and (ii) 2,50,044 equity shares of the Company to Purchaser 2 (collectively, “**Share Sale**”), pursuant to the SPA, has been taken on record by the Board at its meeting dated 30 May 2025 and Purchaser 1 has obtained sole control over the Company.

The Seller has been reclassified from the ‘promoter’ category of the Company to the ‘public category’ of the Company in terms of Regulation 31A of the SEBI (LODR) Regulations, as separately intimated by the Company to the Stock Exchanges.

Given the above, the revised shareholding pattern of the Promoters/ Promoter Group of the Company is as under:

S. No.	Name of the Promoter/ Promoter Group	No. of Equity Shares	Shareholdings in %
1.	Dr. B. S. Ajaikumar (Promoter)	1,44,98,715	10.40
2.	Purchaser 1 i.e., Hector Asia Holdings II Pte. Ltd. (Promoter)	7,16,77,991	~51.41%
3.	Ms. Bhagya A Ajaikumar (Promoter Group)	1,795	0.00
4.	Ms. Anjali Ajaikumar Rossi (Promoter Group)	1,000	0.00

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



5.	Ms. Aagnika Ajaikumar (Promoter Group)	3,27,258	0.23
6.	Ms. Asmitha Ajaikumar (Promoter Group)	3,27,259	0.23
7.	Purchaser 2 i.e., KIA EBT II Scheme 1 (Promoter Group)	2,50,044	~0.18%
8.	Hector Asia Holdings I Pte. Ltd. (the holding company of Purchaser 1) (Promoter Group)	Nil	0.00

B. Change in directors, chief executive officer

Set out below are the changes in the Directors on the Board of Directors of the Company:

1. Resignation of Non-Executive Non-Independent Directors

The following Non-Independent and Non-Executive Directors being nominee directors of the Seller, have tendered their resignation from the Board of the Company, which was accepted by the Board in its meeting dated 30 May 2025, with effect from 30 May 2025.

- (a) Mr. Siddharth Tapaswin Patel (DIN: 07803802)
- (b) Mr. Amit Soni (DIN: 05111144)

The disclosures required under Regulation 30 of the SEBI Listing Regulations and SEBI circular dated July 13, 2023 (SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123) in respect of the resignation of directors are enclosed herewith as **Annexure I**. Resignation letters pursuant to Regulation 30 and Schedule III of the SEBI Listing Regulations are enclosed herewith as **Annexures II and III**.

2. Appointment of Non-Executive Non-Independent Directors

Based on the recommendations of the Nomination and Remuneration Committee of the Company, the Board has, in its meeting dated 30 May 2025, approved appointment of the following Directors as additional directors (Non-Independent and Non-Executive Director) nominee directors of Hector Asia Holdings II Pte. Ltd., on the Board of the Company with effect from 30 May 2025, subject to obtaining shareholders' approval within 3 months.

- (a) Ms. Simrun Mehta (DIN: 09118938)
- (b) Mr. Akshay Tanna (DIN: 02967021)

In accordance with the circular dated June 20, 2018, issued by the Stock Exchanges, we hereby confirm that none of the above-stated Directors are debarred from holding the office of Director by virtue of any order passed by SEBI or any other such authority.



The composition of the Board of Directors of the Company continues to be in compliance with the requirements prescribed under the Companies Act, 2013 and the SEBI Listing Regulations.

The disclosures required under Regulation 30 of the SEBI Listing Regulations and the SEBI circular dated July 13, 2023 (SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123) for appointment of directors along with brief profiles, are enclosed herewith as **Annexure IV**.

3. Appointment of Non-Executive Non-Independent Directors

The Board of the Company had noted given the Share Sale transaction: (a) Dr. B. S. Ajaikumar and Mrs. Anjali Rossi have ceased to hold the position of whole-time Directors; (b) Dr. B. S. Ajaikumar has ceased to be designated as executive chairman of the Board of the Company; and (c) the employment agreements dated: (i) 28 June 2023 executed between the Company and Dr. B. S. Ajaikumar; and (ii) 28 March 2023 executed between the Company and Mrs. Anjali Rossi, stand terminated.

- (a) The Board has, in its meeting dated 30 May 2025, approved the appointment of Dr. B.S. Ajaikumar (DIN: 00713779) who shall not be liable to retire by rotation so that notwithstanding termination of his employment agreements executed with the Company, he shall continue to be a director of the Company, subject to the approval of the members of the Company which shall be obtained within three months from the date hereof.
- (b) The Board has, in its meeting dated 30 May 2025, approved the appointment of Mrs. Anjali Ajaikumar Rossi (DIN: 08057112) who shall be liable to retire by rotation so that notwithstanding termination of her employment agreements executed with the Company, she shall continue to be a director of the Company, subject to the approval of the members of the Company which shall be obtained within three months from the date hereof.

Based on the recommendations of the Nomination and Remuneration Committee of the Company, the Board has, in its meeting dated 30 May 2025, approved re-designation of the above-stated Directors as directors (Non-Independent and Non-Executive Director) on the Board of the Company with effect from 30 May 2025, subject to obtaining shareholders' approval within 3 months.

Further, the Board has, in its meeting dated 30 May 2025, also approved appointment of Dr. B.S. Ajaikumar as the non-executive chairman of the Board of the Company for a period up to June 30, 2030.

In accordance with the circular dated June 20, 2018, issued by the Stock Exchanges, we hereby confirm that none of the above-stated Directors are debarred from holding the office of Director by virtue of any order passed by SEBI or any other such authority.

As on date, the composition of the Board of Directors of the Company continues to be in compliance with the requirements prescribed under the Companies Act, 2013 and the SEBI Listing Regulations.



The disclosures required under Regulation 30 of the SEBI Listing Regulations and SEBI circular dated July 13, 2023 (SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123) for appointment of directors along with brief profiles, are enclosed herewith as **Annexure V**.

4. Appointment of an Executive Director

Based on the recommendations of the Nomination and Remuneration Committee, the Board has *inter alia* subject to: (a) appointment of an individual to serve as an independent director on the Board; and (b) subject to obtaining the shareholders' approval within 3 months, approved the appointment of Dr. Manish Mattoo (DIN: 08431924), a nominee of Hector Asia Holdings II Pte. Ltd. as an additional director (Executive Director) on the Board of the Company with effect from 30 June 2025 or completion of other appointment related processes, whichever is later.

In accordance with the circular dated June 20, 2018, issued by the Stock Exchanges, we hereby confirm that the above-stated Director is not debarred from holding the office of Director by virtue of any order passed by SEBI or any other such authority and is not related to any of the Directors of the Company.

As on date, the composition of the Board of Directors of the Company continues to be in compliance with the requirements prescribed under the Companies Act, 2013 and the SEBI Listing Regulations.

The disclosures required under Regulation 30 of the SEBI Listing Regulations and SEBI circular dated July 13, 2023 (SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123), for appointment of director along with brief profile, is enclosed herewith as **Annexure VI**.

5. Resignation of the Chief Executive Officer of the Company

Mr. Meghraj Arvindrao Gore has tendered his resignation as a chief executive officer of the Company, which was accepted by the Board in its meeting dated 30 May 2025, with effect from 30 June 2025.

The disclosures required under Regulation 30 of the SEBI Listing Regulations and SEBI circular dated July 13, 2023 (SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123) in respect of resignation of the Chief Executive Officer is enclosed herewith as **Annexure VII**. Resignation letter pursuant to Regulation 30 and Schedule III of the SEBI Listing Regulations is enclosed herewith as **Annexure VIII**.

6. Appointment of the Chief Executive Officer of the Company

Based on the recommendations of the Nomination and Remuneration Committee, the Board has approved appointment of Mr. Manish Mattoo, as the Chief Executive Officer of the Company, with effect from 30 June 2025.



The disclosures required under Regulation 30 of the SEBI Listing Regulations and SEBI circular dated July 13, 2023 (SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123) in respect of resignation of the Chief Executive Officer is enclosed herewith as **Annexure IX**.

C. Amendment to the articles of association of the Company

The Board has in its meeting dated 30 May 2025 approved adoption of the amended articles of association of the Company, subject to obtaining shareholders' approval.

The disclosures required under Regulation 30 of the SEBI Listing Regulations and SEBI circular dated July 13, 2023 (SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123) with respect to the brief details of the amendments is enclosed herewith as **Annexure X**.

D. Consultancy arrangements with Dr. BS Ajaikumar and Mrs. Anjali Rossi

The Board has in its meeting dated 30 May 2025 approved the engagement of Dr. BS Ajaikumar and Mrs. Anjali Rossi as consultants, subject to obtaining shareholders' approval. The consultancy agreements have been executed by the Company with Dr. BS Ajaikumar and Mrs. Anjali Rossi, respectively, and the consultant arrangements will be effective once the shareholders' approval is obtained.

Kindly take the intimation on record and acknowledge receipt of the same.

Yours truly,

For **Healthcare Global Enterprises Limited**

Sunu Manuel
Company Secretary and Compliance Officer



Annexure I

Resignation of Mr. Siddharth Tapaswin Patel as director of the Company

Sr. No.	Details Required	Particulars
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	As mentioned in the enclosed resignation letter
2.	Date of appointment / cessation (as applicable) and terms of appointment	30 May 2025
3.	Brief profile (in case of appointment)	Not applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

Resignation of Mr. Amit Soni as director of the Company

Sr. No.	Details Required	Particulars
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	As mentioned in the enclosed resignation letter
2.	Date of appointment / cessation (as applicable) and terms of appointment	30 May 2025
3.	Brief profile (in case of appointment)	Not applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

Date: May 30, 2025

To,

The Board of Directors,
HealthCare Global Enterprises Limited
Corporate Office: No. 3, Ground Floor, Tower Block,
Unity Buildings Complex, Mission Road,
Bengaluru – 560027,
Karnataka, India

Subject: Resignation as Director of HealthCare Global Enterprises Limited ("**Company**")

Dear Sir(s),

1. I, Siddharth Tapaswin Patel, was appointed as a Non-Executive Nominee Director on the board of directors of the Company ("**Board**") with effect from July 20, 2020, nominated by Aceso Company Pte. Ltd., in accordance with the articles of association of the Company. Aceso Company Pte. Ltd is also a 'Promoter' of the Company.
2. Pursuant to the share purchase agreement dated February 23, 2025, executed by and amongst Hector Asia Holdings II Pte. Ltd., KIA EBT II Scheme 1, Aceso Company Pte. Ltd., and the Company ("**SPA**"), upon the occurrence of First Closing (*as defined in the SPA*) under the SPA, Aceso Company Pte. Ltd. will cease to be a 'Promoter' of the Company and will cease to have the right to appoint nominee directors on the Board.
3. Accordingly, I wish to step down from the position of Non-Executive Nominee Director from the Board including all the committees and / or sub committees of the Board which I was a part of, with effect from the earlier of (a) the board of directors of the Company taking on record my resignation through a board resolution; or (b) the close of business hours on May 30, 2025.
4. I confirm that I have no claims or demands against the Company and the Target Group Entities (*as defined in the SPA*), including with respect to compensation for loss of office, arrears of remuneration or reimbursement of outstanding expenses.
5. Kindly accept and take on record my resignation from the directorship of the Company with effect from the date set out in paragraph 3 above and take necessary steps to formalize the above including necessary regulatory filings.
6. I wish the Company all the best for its future endeavours.

Thanking You,

Yours faithfully,



Name: Siddharth Tapaswin Patel

Date: May 30, 2025

To,

The Board of Directors,
HealthCare Global Enterprises Limited
Corporate Office: No. 3, Ground Floor, Tower Block,
Unity Buildings Complex, Mission Road,
Bengaluru – 560027,
Karnataka, India

Subject: Resignation as Director of HealthCare Global Enterprises Limited ("**Company**")

Dear Sir(s),

1. I, Amit Soni, was appointed as a Non-Executive Nominee Director on the board of directors of the Company ("**Board**") with effect from July 20, 2020, nominated by Aceso Company Pte. Ltd., in accordance with the articles of association of the Company. Aceso Company Pte. Ltd is also a 'Promoter' of the Company.
2. Pursuant to the share purchase agreement dated February 23, 2025, executed by and amongst Hector Asia Holdings II Pte. Ltd., KIA EBT II Scheme 1, Aceso Company Pte. Ltd., and the Company ("**SPA**"), upon the occurrence of First Closing (*as defined in the SPA*) under the SPA, Aceso Company Pte. Ltd. will cease to be a 'Promoter' of the Company and will cease to have the right to appoint nominee directors on the Board.
3. Accordingly, I wish to step down from the position of Non-Executive Nominee Director from the Board including all the committees and / or sub committees of the Board which I was a part of, with effect from the earlier of (a) the board of directors of the Company taking on record my resignation through a board resolution; or (b) the close of business hours on May 30, 2025.
4. I confirm that I have no claims or demands against the Company and the Target Group Entities (*as defined in the SPA*), including with respect to compensation for loss of office, arrears of remuneration or reimbursement of outstanding expenses.
5. Kindly accept and take on record my resignation from the directorship of the Company with effect from the date set out in paragraph 3 above and take necessary steps to formalize the above including necessary regulatory filings.
6. I wish the Company all the best for its future endeavours.

Thanking You,

Yours faithfully,



Name: Amit Soni



Annexure IV

Appointment of Mrs. Anjali Ajaikumar Rossi as a Non-Executive Non-Independent director of the Company

Sr. No.	Details Required	Particulars
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Pursuant to the promoter agreement
2.	Date of appointment /re-appointment/ cessation (as applicable) and terms of appointment	30 May 2025 and 5 years or such shorter period under the promoter agreement Liable to retire by rotation
3.	Brief profile (in case of appointment)	Please refer to Annexure A
4.	Disclosure of relationships between directors (in case of appointment of a director)	Anjali is the daughter of Dr. B.S. Ajaikumar

Appointment of Dr. B.S. Ajaikumar as a Non-Executive Non-Independent director of the Company

Sr. No.	Details Required	Particulars
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Pursuant to the promoter agreement
2.	Date of appointment /re-appointment/ cessation (as applicable) and terms of appointment	30 May 2025 Not liable to retirement by rotation
3.	Brief profile (in case of appointment)	Please refer to Annexure A
4.	Disclosure of relationships between directors (in case of appointment of a director)	Dr. B.S. Ajaikumar is the father of Anjali



Annexure A

Brief profile of Dr. B. S. Ajaikumar

Dr Ajaikumar founded the Company and his contributions to the field of cancer care in India and his success as a first-generation physician entrepreneur have been widely recognized. He has been awarded the Ernst and Young Entrepreneur of the Year Award, the CII Regional Emerging Entrepreneurs Award, and the BC Roy Award by the Indian Science Monitor. Dr Ajaikumar is also the recipient of the Karnataka Rajyotsava Award.

Dr Ajaikumar has been a practicing oncologist in the US and India for over three decades. He completed his residency training in Radiotherapy from the MD Anderson Hospital and Tumour Institute of the University of Texas, and his residency training in Oncology from the University of Virginia Hospital, Charlottesville. He received his MBBS from St. Johns Medical College, Bangalore.

Brief profile of Mrs. Anjali Ajaikumar Rossi

Mrs. Anjali Ajaikumar is a healthcare professional. In her fifteen years of experience as an administrator and strategist she has worked extensively to redefine the patient experience for cancer patients in India.

With her deep understanding of the expectations of patients and caregivers, Anjali has set up centralized divisions for quality assurance, clinical excellence, operations, nursing, and other functions to drive organizational efficiency, employee engagement, patient satisfaction, and continuous advancements in the quality of care across HCG centres in India and overseas.

Anjali is an MBA graduate in Entrepreneurship from Babson College and has valuable insights into project consulting and leadership from her past stints in the US. She is a mentor to start-ups within the healthcare space, and brings a unique perspective along with a wealth of experience to provide guidance and strategic support to emerging entrepreneurs.

She is committed to raising awareness about cancer issues, and has organized numerous fundraising programs to aid financially challenged patients. In her role with the non-profit International Human Development and Upliftment Academy, Anjali is active in promoting rural education, fostering women empowerment, and creating awareness about environmental issues.



Annexure V

Appointment of Ms. Simrun Mehta as an additional director (Non-Independent and Non-Executive Director), as a nominee of Hector Asia Holdings II Pte. Ltd. on the Board of directors of the Company

Sr. No.	Details Required	Particulars
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Pursuant to the SPA
2.	Date of appointment /cessation (as applicable) and term of appointment	30 May 2025 Retirement by rotation
3.	Brief profile (in case of appointment)	<p>Ms. Simrun Mehta presently serves as the Managing Director of KKR India Advisors Private Limited. Ms. Mehta joined KKR in 2012 and is a Managing Director on the Private Equity team, with 17 years of experience in financial services in India.</p> <p>Ms. Mehta has been closely involved in KKR's investments across multiple sectors, and currently leads KKR's investments in India in the consumer, retail and hospitals sectors. Ms. Mehta currently serves on the boards of Vini Cosmetics, Lighthouse Learning, Avendus Capital, Baby Memorial Hospital, RE Sustainability, Ness Digital Engineering and Serentica Renewables.</p> <p>Prior to joining KKR, Ms. Mehta worked with Nomura's fixed income team and the commodities division of Lehman Brothers. Ms. Mehta holds a Bachelor of Arts (Honours) in Mathematics from St. Stephen's College, University of Delhi.</p>
4.	Disclosure of relationships between directors (in case of appointment of a director)	None



Appointment of Mr. Akshay Tanna as an additional director (Non-Independent and Non-Executive Director), as a nominee of Hector Asia Holdings II Pte. Ltd. on the Board of directors of the Company

Sr. No.	Details Required	Particulars
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Pursuant to the SPA
2.	Date of appointment / cessation (as applicable) and term of appointment	30 May 2025 Retirement by rotation
3.	Brief profile (in case of appointment)	<p>Mr. Akshay Tanna joined KKR Mumbai office in 2023 as Partner & Head of India Private Equity.</p> <p>Prior to joining KKR, Akshay spent more than 13 years with TPG and was most recently a Partner in its India office. Earlier in his career, Akshay worked as an Associate in Investment Banking in the Financial Institutions Group with Deutsche Bank, New York. Akshay started his career as an Associate in Investment Banking at Merrill Lynch, New York & London.</p> <p>Mr. Tanna currently serves on the Board of Directors of J B Chemicals and Pharmaceuticals Limited, Infix Services Private Limited, Baby Memorial Hospital Limited, Advanta Enterprises Limited, Avendus Capital Private Limited, Healthium Medtech Limited, Rebel Foods Private Limited, Darwinbox Digital Solutions Private Ltd and Vini Cosmetics Private Limited.</p> <p>Mr. Tanna earned a BS in Economics, Magna Cum Laude from The Wharton School of the University of Pennsylvania.</p>
4.	Disclosure of relationships between directors (in case of appointment of a director)	None



Annexure VI

Appointment of Dr. Manish Mattoo (DIN: 08431924) as an additional director (Non-Independent and Executive Director), as a nominee of Hector Asia Holdings II Pte. Ltd. on the Board of directors of the Company

Sr. No.	Details Required	Particulars
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Pursuant to the SPA
2.	Date of appointment / cessation (as applicable) and term of appointment	With effect from 30 June 2025 and for a period 5 years Retirement by rotation
3.	Brief profile (in case of appointment)	Please refer to Annexure B
4.	Disclosure of relationships between directors (in case of appointment of a director)	None



Annexure B

Brief profile of Dr. Manish Mattoo

Dr. Manish Mattoo is a seasoned healthcare business leader with over two decades of multifaceted experience. He has combined his clinical knowledge and business acumen to excel in healthcare management. His repertoire includes driving growth in mature hospital systems, creating competitive advantage in complex markets, successfully managing physician practices, revitalising underperforming hospitals, optimising supply chains, pioneering healthcare IT solutions, and much more. He is unwavering in his commitment to delivering high-quality care efficiently, placing patient interests at the forefront and building strong high-performance teams. He is a digital health evangelist who has introduced several innovations in healthcare operations that have enhanced patient experiences while achieving substantial savings.

In his previous role he worked as Regional Chief Executive Officer at Apollo Hospitals, Karnataka & Central Region. He steered the business in these two large regions spanning multiple cities, several hospitals and a cumulative bed count of 2000+ beds across different formats. He led a team of over 6,000 dedicated associates including 500+ doctors delivering impressive financial results and high patient satisfaction ratings consistently.

Prior to his role at Apollo Hospitals, Dr. Manish served as Vice-President at Fortis Healthcare, where he gained extensive experience spanning various geographies and functions, including operations, business strategy, supply chain management, and internal audit. He has also held leadership roles at healthcare majors such as Medtronic and Monitor Group. Before foraying into healthcare management, he worked as a clinician for several years in prestigious institutions like PGI, Chandigarh and Civil Hospital, Ahmedabad.

Dr. Manish is a distinguished alumnus of the Indian School of Business (ISB), holding an MBA with a dual major in Finance and Strategy & Leadership. He earned his MBBS and MD in Anaesthesiology from BJ Medical College, Ahmedabad, solidifying his foundation in both clinical and management disciplines. Dr. Manish has also completed a certificate course in Internal Audit from the Institute of Internal Auditors.



Annexure VII

Resignation of Mr. Meghraj Arvindrao Gore as the Chief Executive Officer of the Company

Sr. No.	Details Required	Particulars
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	As stated in the resignation letter
2.	Date of appointment /cessation (as applicable) and terms of appointment	With effect from 30 June 2025
3.	Brief profile (in case of appointment)	Not applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	None

Date: 30 May 2025

To,
The Board of Directors,
HealthCare Global Enterprises Limited

Sub: Letter of Resignation from the position of CEO

Dear Members,

After careful consideration, I have decided to step down from my position as Chief Executive Officer of Healthcare Global Enterprises Limited (HCG), effective June 30, 2025, to pursue alternate career opportunities and personal goals.


Serving as the CEO of HCG has been one of the most meaningful chapters of my professional life. It has been an honour and a privilege to lead this passionate, mission driven, high performing team and be a part of HCG's remarkable growth story. I feel proud that together we have achieved many milestones and built something that truly makes a difference in the lives of cancer patients and their families across India. I remain confident that HCG is well-positioned to continue its journey of growth in future.

I am deeply grateful for the trust, support, and collaboration I've experienced from the Board, our shareholders, dedicated clinicians and nurses, 6,000+ HCGians, and partners throughout my tenure. I am committed to ensuring a smooth transition and will work closely with the leadership team over the coming weeks to facilitate the handover process.

Though I will no longer be at the helm, I will always remain a well-wisher of HCG and the extraordinary mission it continues to fulfil. I wish the organisation continued growth and success in all its future endeavours.

You are requested to acknowledge receipt of this letter and undertake the required filings and intimations, as required.

Thanking you,
Yours faithfully,



Meghraj Arvindrao Gore
Chief Executive Officer



Annexure IX

Appointment of Dr. Manish Mattoo as the Chief Executive Officer of the Company

Sr. No.	Details Required	Particulars
1.	Reason for change viz- appointment, resignation, removal, death or otherwise	Pursuant to the SPA
2.	Date of appointment / cessation (as applicable) and terms of appointment	With effect from 30 June 2025 As recommended by the Nomination & Remuneration Committee and approved by Audit Committee and the Board of Directors.
3.	Brief profile (in case of appointment)	Please refer to Annexure B above
4.	Disclosure of relationships between directors (in case of appointment of a director)	None



Annexure X

Amendment to the Articles of Association of the Company

The Amended Articles contain *inter alia*:

- (a) clauses on management and composition of the Board of the Company and its subsidiaries;
- (b) subject to applicable law, the right of Dr. BS Ajaikumar to be appointed as the non-executive chairman of the Board until June 30, 2030 (which may be renewed by mutual agreement of the parties) and subject to receipt of requisite corporate approvals, subject to applicable law;
- (c) reserved matter rights of Purchaser 1 in relation to the Target Group Entities i.e., restrictions on any action or decision being taken (including any steps being commenced or taken for giving effect to any action or decision) whether by the board of directors, any director, any committee, the senior management or shareholders of the Target Group Entities, or any of the employees, officers, managers of the Target Group Entities unless the approval of the Board of the Company (including at least 1 nominee director of Purchaser 1), whether in a meeting or by circular resolution, is obtained over *inter alia*: (i) incurring net indebtedness or lending, creating pledge or encumbrance which exceeds certain amounts; (ii) commencement or acquisition of or investing in a new line of business/activity or closure or winding down of an existing business/activity or direct or indirect (partial or full) exit of a business of any Target Group Entities; (iii) any alteration to the capital structure of a Target Group Entity, declaration of dividend, issuance or allotment of employee stock options; (iv) sale, transfer, disposition, slump sale, pledge or encumbrance of securities or any business of any Target Group Entity;
- (d) information rights of the Purchaser 1 and Purchaser 2 requiring the Company and the Target Group Entities to provide such information and access to properties, assets, records and documents as the Purchaser 1, Purchaser 2 or the Purchaser 1 nominee directors may request subject to applicable law; and
- (e) mandatory sell down obligation of the Seller.

For the purposes of this Annexure X,

Target Group Entities means the Company, its direct and indirect subsidiaries and limited liability partnerships, which partnerships are controlled by the Company